title: Molecular Pathology: Prognostic and Diagnostic Genomic Markers for Myeloid Neoplasms.
abstract: Application of next-generation sequencing (NGS) on myeloid neoplasms has expanded our knowledge of genomic alterations in this group of diseases. Genomic alterations in myeloid neoplasms are complex, heterogeneous, and not specific to a disease entity. NGS-based panel testing of myeloid neoplasms can complement existing diagnostic modalities and is gaining acceptance in the clinics and diagnostic laboratories. Prospective, randomized trials to evaluate the prognostic significance of genomic markers in myeloid neoplasms are under way in academic medical centers.
authors: Center for Advanced Molecular Diagnostics, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA. Electronic address: fkuo@partners.org.
authors: Frank C
authors: FC
authors: Kuo
mesh_terms: D014408:Biomarkers, Tumor / Q000235:genetics*; D004252:DNA Mutational Analysis; D023281:Genomics; D019337:Hematologic Neoplasms / Q000175:diagnosis* / Q000235:genetics / Q000473:pathology*; D059014:High-Throughput Nucleotide Sequencing; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis* / Q000235:genetics / Q000473:pathology*; D009154:Mutation / Q000235:genetics*; D057089:Pathology, Molecular; D011379:Prognosis
chemical_list: D014408:Biomarkers, Tumor
keywords: Copy number variation; Genomic alterations; Mutations; Myeloid neoplasms; Next-generation sequencing